This feature article in Chemistry Today, highlights our peptide chemistry team’s extensive expertise in peptide and macrocyclic drug discovery in a range of therapeutic areas and with an impressive track record in the clinic.
Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key emerging trends within the cancer field and assesses AI’s potential as a truly transformative asset within the drug developer’s toolbox.
Article published on Pharma Boardroom – 07/10/2021
Read the original article on Pharma Boardroom